Alzheimer's fail crushes small biotech's share price to nearly penny stock
Alzheimer’s research has wiped out another biotech’s market cap.
Synaptogenix, a small startup based out of New York, reported a Phase II Alzheimer’s fail Friday morning, sending shares spiraling nearly 75%. The study had attempted to see whether the drug bryostatin-1 could improve patient scores on a test called the Severe Impairment Battery (SIB) total score assessment by a significant margin after 28 weeks.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.